Trial · NCT01268683
Results by group49
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 49
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Rate of Enrollment | RP-1127 (Glyburide for Injection) | 9.6 | Months | ||
| Percentage of Enrolled Participants to Screened Participants | RP-1127 (Glyburide for Injection) | 5.7 | Percentage of Participants | ||
| Percentage of Participants Completing 90-Day Follow-Up | RP-1127 (Glyburide for Injection) | 80 | Percentage of Participants | ||
| Percentage of Dose Reductions/ Dose Suspensions | RP-1127 (Glyburide for Injection) | 0 | Percentage of Participants | ||
| Percentage of Participants With All Four MRI Assessments Per Protocol | RP-1127 (Glyburide for Injection) | 90 | Percentage of Participants | ||
| Number of MRI Assessments Per Participant | RP-1127 (Glyburide for Injection) | 3.9 | Full Range 3 to 4 | Number of MRIs | |
| Percentage of Participants Requiring One or More Hypoglycemia Treatments | RP-1127 (Glyburide for Injection) | 0 | Percentage of Participants | ||
| Percentage of Participants With Pre-specified Adverse Events Associated With Glyburide According to Protocol | RP-1127 (Glyburide for Injection) | 0 | Percentage of Participants | ||
| Number of Participants With Adverse Events and Serious Adverse Events | RP-1127 (Glyburide for Injection) | Adverse Events | 10 | Number of Participants | |
| Number of Participants With Adverse Events and Serious Adverse Events | RP-1127 (Glyburide for Injection) | Serious Adverse Events | 3 | Number of Participants | |
| Infarcted Hemisphere Volume | RP-1127 (Glyburide for Injection) | Baseline | 135.20 | Standard Deviation 27.19 | Centimeters cubed (cm^3) |
| Infarcted Hemisphere Volume | RP-1127 (Glyburide for Injection) | Day 1 | 156.78 | Standard Deviation 35.09 | Centimeters cubed (cm^3) |
| Infarcted Hemisphere Volume | RP-1127 (Glyburide for Injection) | Day 2 | 165.38 | Standard Deviation 34.17 | Centimeters cubed (cm^3) |
| Infarcted Hemisphere Volume | RP-1127 (Glyburide for Injection) | Day 3 | 181.71 | Standard Deviation 33.90 | Centimeters cubed (cm^3) |
| Absolute Diffusion Weighted Imaging (DWI) Lesion Volume | RP-1127 (Glyburide for Injection) | Baseline | 101.76 | Standard Deviation 22.57 | Cm^3 |
| Absolute Diffusion Weighted Imaging (DWI) Lesion Volume | RP-1127 (Glyburide for Injection) | Day 1 | 141.62 | Standard Deviation 44.05 | Cm^3 |
| Absolute Diffusion Weighted Imaging (DWI) Lesion Volume | RP-1127 (Glyburide for Injection) | Day 2 | 152.31 | Standard Deviation 49.26 | Cm^3 |
| Absolute Diffusion Weighted Imaging (DWI) Lesion Volume | RP-1127 (Glyburide for Injection) | Day 3 | 169.73 | Standard Deviation 54.28 | Cm^3 |
| Change From Baseline in DWI Lesion Volume | RP-1127 (Glyburide for Injection) | 60.30 | Standard Deviation 41.37 | Cm^3 | |
| Midline Shift | RP-1127 (Glyburide for Injection) | Baseline | 0.56 | Standard Deviation 1.13 | Millimeters (mm) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01268683/results